2003 JUN 9 - (NewsRx.com & NewsRx.net) -- Regeneron Pharmaceuticals is the target of a securities class action lawsuit from investors claiming the company and its leadership made misleading and false statements regarding AXOKINE, a diet drug.
The complaint alleges that Regeneron officials claimed that the drug would help obese patients lose weight better than a placebo and would generate more than $500 million in annual sales. However, according to the complaint, two-thirds of …
No comments:
Post a Comment